Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| OPERATING EXPENSES: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| Research and development | 206,952 | 161,308 | 385,748 | 320,039 |
| Selling, general and administrative | 395,549 | 232,279 | 653,839 | 438,395 |
| Intangible asset amortization | 73,492 | 4,846 | 77,975 | 9,693 |
| Total operating expenses | 878,788 | 548,523 | 1,515,356 | 1,069,775 |
| INCOME FROM OPERATIONS | 110,920 | 276,887 | 240,560 | 500,780 |
| Interest income | 10,480 | 18,827 | 33,040 | 37,840 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's SG&A?
- BioMarin Pharmaceuticals (BMRN) reported SG&A of $395.55M in Q2 2026.
- How has BioMarin Pharmaceuticals's SG&A changed year-over-year?
- BioMarin Pharmaceuticals's SG&A increased by 70.3% year-over-year, from $232.28M to $395.55M.
- What is the long-term trend for BioMarin Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's SG&A has grown at a 11.0% compound annual growth rate (CAGR), from $759.38M to $1.15B.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about BioMarin Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude